ProGo Menopause Wellbeing Study
← catalyst calendarNCT07611305 · readout ≤ 134 d
Sponsored by Hofseth Biocare ASA (industry) · HBC.OL — their whole pipeline →. With Alethios, Inc..
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
100estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Menopause Related Conditions
Interventions
- Dietary supplement: Salmon protein hydrolysate (SPH) powder formulated into a tablet format
- Dietary supplement: Microcrystalline Cellulose
Primary outcomes
what the primary-completion date above is the date OFChange in body mass index (BMI)
measured 18 weeks
Mean change in menopause-specific quality of life (MENQoL) questionnaire total score
measured 18 weeks
Permalink · HBC.OL's whole pipeline · Catalyst calendar · Every registered study · What changed